Search results for "Forensic"

showing 10 items of 1701 documents

The face of conflict: Significant sharp force trauma to the mid-facial skeleton in an individual of probable 16th–17th century date excavated from By…

2016

A variety of injuries have always been associated with violence, consequences of which people had to deal with. In this paper we present a complex of craniofacial and dental injuries resulted from sharp force trauma. The basis of our study was historical skeletal material excavated from archeological site in Byczyna (11th–17th century), Poland. An individual whose skeleton was exhumed from the grave No. 610 exhibited healed, oblique trauma of the left maxilla, damage to the crowns of right central and lateral incisors and concomitant luxation of the right maxillary central incisor. We describe the mechanism of this trauma and complications that resulted from damage to the masticatory appara…

Male010506 paleontologyArcheologyHistoryPaleopathologyDentistrywound healingViolence01 natural sciencesPathology and Forensic MedicineConflict PsychologicalHistory 17th Centurystomatognathic systemIncisordentoalveolar traumaviolence related traumaMaxillamedicineSharp forceHumans0601 history and archaeologyMaxillary central incisortooth injuryCraniofacialPaleopathology0105 earth and related environmental sciences060102 archaeologybusiness.industry06 humanities and the artsMasticatory forceIncisorstomatognathic diseasesmedicine.anatomical_structureHistory 16th CenturyMaxillaFacial skeletonPolandbusinessInternational Journal of Paleopathology
researchProduct

PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: A expression patterns and clinical implications

2018

Undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), a variant of pancreatic ductal adenocarcinoma (PDAC), has a striking genetic similarity to PDAC but a significantly improved overall survival. We hypothesize that this difference could be due to the immune response to the tumor, and as such, we investigated the expression of PD-1, PD-L1, and CD163 in a series of UCOGC. To this aim, 27 pancreatic UCOGCs (11 pure and 16 PDAC-associated), 5 extrapancreatic tumors with osteoclast-like giant cells and 10 pancreatic anaplastic carcinomas were immunostained using antibodies against PD-1, PD-L1, and CD163. In pancreatic UCOGCs, PD-L1 was expressed in neoplastic cells of 17 (63%) o…

Male0301 basic medicineIndianaProgrammed Cell Death 1 ReceptorOsteoclast; PDAC; Pancreatic Cancer; Tumor-Associated Macrophages; UCOGCOsteoclastsGiant CellsB7-H1 Antigen0302 clinical medicineTumor-Associated MacrophagesTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]LymphocytesAged 80 and overbiologyTumor-associated macrophagesCell DifferentiationMiddle AgedOsteoclast; Pancreatic cancer; PDAC; Tumor-associated macrophages; UCOGC; 2734ImmunohistochemistryEuropePhenotypemedicine.anatomical_structure030220 oncology & carcinogenesisOsteoclastFemaleAntibodyCarcinoma Pancreatic DuctalAdult2734Antigens Differentiation MyelomonocyticReceptors Cell SurfaceUCOGCPathology and Forensic MedicinePancreatic Cancer03 medical and health sciencesImmune systemAll institutes and research themes of the Radboud University Medical CenterAntigens CDOsteoclastPD-L1Pancreatic cancerBiomarkers TumormedicineHumansHistiocyteAgedNeoplasm StagingPDACHistiocytesPancreatic cancermedicine.diseasePancreatic Neoplasms030104 developmental biologyGiant cellCancer researchbiology.proteinCD163
researchProduct

Performance of Finnish biobanks in nationwide pulmonary carcinoid tumour research

2019

Finnish hospital-integrated biobanks administer millions of formalin-fixed paraffin-embedded tissue samples collected within the clinical diagnostics. According to the Finnish Biobank Act, these samples can be coupled with patients’ clinical follow-up data and the data retrieved from national health registries. We collected a nationwide pulmonary carcinoid tumour series from Finnish biobanks to study prognostic factors as well as to explore how the number of tumours found in the Finnish biobanks corresponds to the number of tumours registered by the Finnish Cancer Registry (FCR). Finnish biobanks identified 88% of the tumours registered by the FCR and were able to deliver 63%. The main reas…

Male0301 basic medicineLung NeoplasmsProliferation indexbiopankitDiseaseNeuroendocrine tumorskeuhkosyöpäPulmonary carcinoidTumour tissue0302 clinical medicineRARERegistriesINDEXFinlandBiological Specimen BanksOUTCOMESrare cancerSURGICAL RESECTIONGeneral MedicineMiddle AgedPrognosisBiobank3. Good healthbiobank030220 oncology & carcinogenesisMediastinal lymph nodeSURVIVALOriginal ArticleFemaleBURDENpulmonary carcinoidAdultmedicine.medical_specialty3122 CancersCarcinoid TumorPathology and Forensic Medicine03 medical and health sciencesInternal medicinemedicineQUALITYHumansharvinaiset tauditMolecular BiologyBiobankbusiness.industryRare cancerennusteetCell Biologymedicine.diseaseCarcinoma NeuroendocrineCancer registryPulmonary carcinoid tumour030104 developmental biologyEXPERIENCEprognosis3111 BiomedicinebusinessNEUROENDOCRINE TUMORSVirchows Archiv
researchProduct

Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status

2019

The CD274 (programmed cell death ligand-1, PD-L1)/PDCD1 (programmed cell death-1, PD-1) pathway is crucial suppressor of the cytotoxic immune response. Antibodies targeting CD274 or PDCD1 have been revealed to be effective in several malignancies. In colorectal cancer, the response to CD274/PDCD1 blockage is associated with microsatellite instability. However, the value of CD274/PDCD1 for predicting response to treatment or survival benefit is still unclear. The aims of the study were (1) to clarify differences in immune microenvironment and expression of checkpoint proteins (CD274/PDCD1) in DNA mismatch repair-proficient, mismatch repair-deficient, and hereditary Lynch syndrome-associated …

Male0301 basic medicineOncologymedicine.medical_specialtyPathologyColorectal cancerProgrammed Cell Death 1 ReceptorCellDNA Mismatch RepairB7-H1 AntigenPathology and Forensic Medicine03 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineImmune systemInternal medicinePD-L1Biomarkers TumorTumor MicroenvironmentmedicineHumansCytotoxic T cellAgedbiologybusiness.industryMicrosatellite instabilityMiddle Agedmedicine.diseaseColorectal Neoplasms Hereditary Nonpolyposis030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisbiology.proteinFemaleDNA mismatch repairAntibodyColorectal Neoplasmsbusiness
researchProduct

Post-Mortem Immunohistochemical Evidence of β2-Adrenergic Receptor Expression in the Adrenal Gland

2019

The evidence from post-mortem biochemical studies conducted on cortisol and catecholamines suggest that analysis of the adrenal gland could provide useful information about its role in human pathophysiology and the stress response. Authors designed an immunohistochemical study on the expression of the adrenal &beta

Male0301 basic medicinePathologyGene ExpressionStimulationlcsh:Chemistry0302 clinical medicineCortex (anatomy)Adrenal Glandspost-mortem analysisReceptorlcsh:QH301-705.5SpectroscopyCause of deathAged 80 and overAdrenal glandβ2-adrenergic receptorsGeneral MedicineMiddle AgedPathophysiologyComputer Science Applicationsmedicine.anatomical_structureimmunohistochemistryImmunohistochemistryFemaleAutopsyAdultmedicine.medical_specialtyAdolescentBiologyArticleCatalysisInorganic ChemistryYoung Adult03 medical and health sciencesSettore MED/43 - Medicina LegalemedicineHumans030216 legal & forensic medicinepost-mortem analysiPhysical and Theoretical ChemistryMolecular BiologyAgedadrenal glandOrganic Chemistry030104 developmental biologylcsh:Biology (General)lcsh:QD1-999adrenal gland; immunohistochemistry; post-mortem analysis; β2-adrenergic receptorsReceptors Adrenergic beta-2HormoneInternational Journal of Molecular Sciences
researchProduct

CpG islands in MyD88 and ASC/PYCARD/TMS1 promoter regions are differentially methylated in head and neck squamous cell carcinoma and primary lung squ…

2021

Abstract Background Patients with head and neck squamous cell carcinoma (HNSCC) can develop lung squamous cell carcinoma (LuSCC), which could be the second primary tumor or HNSCC metastasis. Morphologically it is difficult to distinguish metastatic HNSCC from a second primary tumor which presents a significant diagnostic challenge. Differentiation of those two malignancies is important because the recommended treatments for metastatic HNSCC and primary LuSCC differ significantly. We investigated if the quantification of the promotor methylation status in HNSCC and LuSCC differs. Methods Primary HNSCC (N = 36) and LuSCC (N = 17) were included in this study. Methylation status in the ASC/TMS1…

Male0301 basic medicinePathologyLung NeoplasmsHNSCCEpigenesis GeneticMetastasis0302 clinical medicinePromoter Regions GeneticLungDiagnostic biomarkerPYCARDGeneral MedicineMethylationMiddle AgedGene Expression Regulation NeoplasticBisulfiteCpG siteHead and Neck Neoplasms030220 oncology & carcinogenesisCarcinoma Squamous CellSecond primary tumorFemalelcsh:RB1-214Adultmedicine.medical_specialtyHistologyShort ReportBiologyMethylationPathology and Forensic Medicine03 medical and health sciencesCpG ; diagnostic biomarker ; HNSCC ; lung ; methylation ; second primary tumorCpGClinical Medical Scienceslcsh:PathologymedicineHumansGeneAdaptor Proteins Signal TransducingAgedSquamous Cell Carcinoma of Head and NeckPromotermedicine.diseaseHead and neck squamous-cell carcinomastomatognathic diseases030104 developmental biologyMyeloid Differentiation Factor 88Cancer researchCpG IslandsDiagnostic Pathology
researchProduct

Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer

2020

AbstractImmune suppressing molecule CD73 is overexpressed in various cancers and associated with poor survival. Little is so far known about the predictive value of CD73 in pancreatic ductal adenocarcinoma (PDAC). The purpose of this study was to investigate the prognostic significance of CD73 in PDAC. The study material consisted of 110 radically treated patients for PDAC. Tissue microarray blocks were constructed and stained immunohistochemically using CD73 antibody. Staining intensity and numbers of stained tumour cells, inflammatory cells, stroma, and blood vessels were assessed. High-level CD73 expression in tumour cells was positively associated with PD-L1 expression, perineural invas…

Male0301 basic medicinePathologyentsyymitDatabases Factualpancreatic cancerPerineural invasionB7-H1 Antigen0302 clinical medicineRisk FactorsTumor MicroenvironmentMedicine5'-NucleotidasehaimasyöpäAged 80 and overTissue microarraybiologyGeneral MedicineMiddle AgedPrognosisTreatment OutcomesyöpäsolutChemotherapy AdjuvantimmuunijärjestelmäLymphatic Metastasis030220 oncology & carcinogenesisOriginal ArticleFemaleAntibodyCarcinoma Pancreatic DuctalPD-L1Cell typemedicine.medical_specialtyMicroenvironmentGPI-Linked ProteinsRisk AssessmentPancreaticoduodenectomyPathology and Forensic Medicine03 medical and health sciencesLymphocytes Tumor-InfiltratingPancreatectomyImmune systemStromaPancreatic cancerPD-L1Biomarkers TumorHumansMolecular BiologyAgedNeoplasm Stagingbusiness.industryennusteetPancreatic cancerCell Biologymedicine.disease3126 Surgery anesthesiology intensive care radiologymicroenvironmentPancreatic Neoplasms030104 developmental biologybiology.proteinCD73prognosisNeoplasm Gradingbusiness
researchProduct

Pleural epithelioid angiosarcoma with lymphatic differentiation arisen after radiometabolic therapy for thyroid carcinoma: immunohistochemical findin…

2017

Abstract Background Pleural angiosarcoma is a rare tumor that causes diffuse pleural thickening and effusion, mimicking mesothelioma. Immunohistochemistry is needed to highlight endothelial differentiation. We describe the first case of pleural angiosarcoma with lymphatic differentiation following radiometabolic therapy for thyroid carcinoma. Case presentation A 50-year-old man showed diffuse pleural thickening and effusion. Nine years earlier, he underwent thyroidectomy and radiometabolic therapy for thyroid carcinoma with lymph node metastases. Histologically, the tumor consisted of a solid proliferation of atypical epithelioid cells and anastomosed vascular spaces, lacking of red blood c…

Male0301 basic medicinePathologymedicine.medical_specialtyNeoplasms Radiation-InducedHistologyPleural NeoplasmsHemangiosarcomaReviewRadiometabolic therapyPathology and Forensic MedicineIodine RadioisotopeIodine RadioisotopesThyroid carcinoma03 medical and health sciences0302 clinical medicinelcsh:PathologymedicineHumansAngiosarcomaThyroid NeoplasmsMesotheliomaPleural NeoplasmPleural angiosarcomaPleural NeoplasmLymph nodebusiness.industryThyroid CarcinomaGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistryCarcinoma Papillary030104 developmental biologymedicine.anatomical_structureHemangiosarcomaLymphatic systemThyroid Cancer Papillary030220 oncology & carcinogenesisbusinessEpithelioid celllcsh:RB1-214HumanDiagnostic Pathology
researchProduct

EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer

2018

Epidermal growth factor receptor (EGFR) gene copy number (GCN) increase is associated with a favorable anti-EGFR antibody treatment response in RAS wild-type metastatic colorectal cancer. However, there are limited and comparative data regarding the EGFR GCN in primary colorectal cancer tumors and corresponding metastases or the effect of anti-EGFR antibody treatment on EGFR GCN in recurrent disease. In addition, little is known about the potential EGFR GCN changes during anti-EGFR therapy in comparison with other treatment regimens. EGFR GCN was analyzed by EGFR immunohistochemistry-guided silver in situ hybridization in primary and corresponding recurrent local or metastatic tumors from 8…

Male0301 basic medicineTime FactorsColorectal cancerBLOCKADEGene DosageCetuximabmedicine.disease_causeAntineoplastic Agents Immunological0302 clinical medicinePREDICTS RESPONSEMedicineHETEROGENEITYBENEFITCopy-number variationEpidermal growth factor receptorIn Situ Hybridization FluorescenceAged 80 and overbiologyPanitumumabvasta-aineetMiddle AgedImmunohistochemistry3. Good healthErbB ReceptorsGene Expression Regulation NeoplasticTreatment OutcomeRAS MUTATIONSChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleKRASAntibodyColorectal NeoplasmsAdultgene copy numbermedicine.drug_classCETUXIMAB THERAPY3122 Cancerssilver in situ hybridizationDown-Regulationcolorectal cancerIn situ hybridizationAdenocarcinomaMonoclonal antibodyta3111Pathology and Forensic MedicineProto-Oncogene Proteins p21(ras)03 medical and health sciencesKRASHumansWILD-TYPEMETAANALYSISAgedRetrospective Studiessyöpähoidotbusiness.industrymedicine.diseaseta3122Blockadeperäsuolisyöpä030104 developmental biologymonoclonal antibodyMutationCancer researchbiology.protein3111 BiomedicineNeoplasm Recurrence Localbusinessepidermal growth factor receptorACQUIRED-RESISTANCEHuman Pathology
researchProduct

Pancreatic Protein Tyrosine Phosphatase 1B Deficiency Exacerbates Acute Pancreatitis in Mice

2016

Acute pancreatitis (AP) is a common and devastating gastrointestinal disorder that causes significant morbidity. The disease starts as local inflammation in the pancreas that may progress to systemic inflammation and complications. Protein tyrosine phosphatase 1B (PTP1B) is implicated in inflammatory signaling, but its significance in AP remains unclear. To investigate whether PTP1B may have a role in AP, we used pancreas PTP1B knockout (panc-PTP1B KO) mice and determined the effects of pancreatic PTP1B deficiency on cerulein- and arginine-induced acute pancreatitis. We report that PTP1B protein expression was increased in the early phase of AP in mice and rats. In addition, histological an…

Male0301 basic medicineWistarSystemic inflammationMedical and Health SciencesOral and gastrointestinalMicePathology2.1 Biological and endogenous factorsAetiologyNon-Receptor Type 1CancerMice KnockoutProtein Tyrosine Phosphatase Non-Receptor Type 1Pancreatitis Acute NecrotizingReverse Transcriptase Polymerase Chain ReactionRegular Articlemedicine.anatomical_structureAcute NecrotizingGastrointestinal disorderAcute pancreatitisTumor necrosis factor alphamedicine.symptomPancreashormones hormone substitutes and hormone antagonistsmedicine.medical_specialtyKnockoutInflammationPathology and Forensic MedicineProinflammatory cytokinePancreatic Cancer03 medical and health sciencesRare DiseasesInternal medicinemedicineAnimalsRats WistarAnimalbusiness.industrymedicine.diseaseRatsDisease Models Animal030104 developmental biologyEndocrinologyPancreatitisDisease ModelsPancreatitisProtein Tyrosine PhosphataseDigestive DiseasesbusinessThe American Journal of Pathology
researchProduct